SCHEMBL14601418

SCHEMBL14601418

Oc1ccc2nc(-c3ccncc3)n(CCc3cccs3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.42
JAK1 P23458 2/20 0.42
TYK2 P29597 2/20 0.42
JAK3 P52333 2/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
HPGD P15428 3/20 0.41
TSHR P16473 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
MAOB P27338 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14601427 0.89 ALDH1A1 (0.44) JAK2JAK1TYK2JAK3MEN1
SCHEMBL14601423 0.89 GRIA1 (0.45) JAK2JAK1TYK2JAK3HPGD
SCHEMBL14601424 0.89 HPGD (0.40) JAK2JAK1TYK2JAK3HPGD
SCHEMBL14601428 0.86 KDM4E (0.54) MEN1KMT2AHPGDTSHRKDM4E
SCHEMBL14601420 0.86 KDM4E (0.57) MEN1KMT2AHPGDTSHRKDM4E
SCHEMBL14601416 0.85 KDM4E (0.38) HPGDTSHRKDM4EHSD17B10SMN1; SMN2
SCHEMBL14601419 0.85 KDM4E (0.43) HPGDTSHRKDM4EHSD17B10SMN1; SMN2
SCHEMBL14601422 0.84 PTGS2 (0.43) PIK3CDPIK3CAPIK3CBPIK3CGMAOB
SCHEMBL14601421 0.81 KDM4E (0.39) HPGDTSHRKDM4EHSD17B10SMN1; SMN2
SCHEMBL14601417 0.81 KDM4E (0.38) HPGDTSHRKDM4EHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004713-A1 Therapeutic benimidazole compounds ASTRAZENECA AB (SE) 2007-01-04 US disclosed
US-20070004713-A1 Therapeutic benimidazole compounds ASTRAZENECA AB (SE) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004713-A1 Therapeutic benimidazole compounds ESR2, ESRRA, ESRRB JAK2 567/4885JAK1 1556/4885TYK2 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.